Company Performance Metrics
- Neil Gunn: CEO
- Mark Yandell: Founder & Chief Scientific Officer
We passionately believe that infectious disease patients should be treated with the same precision that cancer patients receive today. As our population increases, our economies become more global, and we continue over-usage of broad-spectrum antibiotics, infectious diseases are going to continue to spread and become more pernicious. Our clinical
practices must evolve with disease to become more precise in our diagnostic and treatment tools. At IDbyDNA, our goal is to accelerate these solutions and uncover the microbial world to reduce infectious disease-associated morbidity and mortality

